← Leaderboards
Ambarish Pandey
Ut Southwestern Medical Center
$2,438,022
Attributed
$4,354,989
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,354,989 · 5
By mechanism
R01$3,631,006 · 2
R03$327,375 · 1
R21$261,322 · 1
T35$135,286 · 1
Top collaborators
- Thomas J Wang5 shared
- Holly M. Holmes1 shared
- Erin Leigh Hommel1 shared
- Elena Volpi1 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Benjamin D Levine$13,458,852
- Thomas J Wang$21,119,622
- Courtney Megan Schroeder$1,356,999
- Jarett D Berry$3,946,135
- Thomas G Gillette$2,049,119
Others in their field
Other Emerging Leaders on “Mortality”
- Chanza Baytop · Westat, Inc.$271,217,917
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Greg Witham · Anp Technologies, Inc.$19,727,817
- Yunda Huang · Fred Hutchinson Cancer Center$19,033,873
- Barbara Halina Braffett · George Washington University$17,931,151
Research focus
MortalityMorbidity - Disease RateRisk FactorsCardiovascular SystemParticipantPrevalenceFollow-UpHeart FailureBlood PressureAdultCostReproducibilityPublic HealthEffective TherapyCommunitiesUptakeTexasUnited StatesVisitCaringEnrollmentMedicalRacial DisparityInhibitor
Grant awards (10)
Polypill strategy for the evidence-based management of heart failure with reduced ejection fraction in an underserved patient population$735,237
R01 · FY2025 · MD · contact PI
Polypill strategy for the treatment of patients after acute coronary syndromes - A multicenter randomized controlled trial$730,276
R01 · FY2025 · HL · contact PI
The University of Texas Medical Student Training on Aging Research (UT-MSTAR) Program$135,286
T35 · FY2025 · AG
Polypill strategy for the evidence-based management of heart failure with reduced ejection fraction in an underserved patient population$696,602
R01 · FY2024 · MD · contact PI
Cardiac biomarkers, intensive blood pressure treatment and risk of adverse cardiovascular outcomes in type 2 diabetes, a secondary analysis of the ACCORD BP$124,885
R21 · FY2024 · HL · contact PI
Polypill strategy for the evidence-based management of heart failure with reduced ejection fraction in an underserved patient population$717,793
R01 · FY2023 · MD · contact PI
Cardiac biomarkers, intensive blood pressure treatment and risk of adverse cardiovascular outcomes in type 2 diabetes, a secondary analysis of the ACCORD BP$136,437
R21 · FY2023 · HL · contact PI
Polypill strategy for the evidence-based management of heart failure with reduced ejection fraction in an underserved patient population$751,098
R01 · FY2022 · MD · contact PI
Evaluation of Racial Differences in Cardiorespiratory Fitness Decline with Aging & Underlying Biological Mechanisms$163,875
R03 · FY2021 · AG · contact PI
Evaluation of Racial Differences in Cardiorespiratory Fitness Decline with Aging & Underlying Biological Mechanisms$163,500
R03 · FY2020 · AG · contact PI